Risperidone Cross-over design query [Design Issues]

posted by ElMaestro  – Denmark, 2008-12-25 08:41 (6397 d 08:32 ago) – Posting: # 2977
Views: 5,813

Since you are comparing fomulations and not metabolisms, I think it would be acceptable (in a purely scientific manner) to simply write in the protocol that poor metabolisers are excluded; this involves testing for it at the time of recruitment.
Then it becomes easier to time the blood sampling and shorten the study/period duration.

EM.

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
280 visitors (0 registered, 280 guests [including 17 identified bots]).
Forum time: 18:13 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5